132 related articles for article (PubMed ID: 32715961)
1. Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis.
Chin L; Hansen RN; Carlson JJ
J Manag Care Spec Pharm; 2020 Aug; 26(8):962-970. PubMed ID: 32715961
[TBL] [Abstract][Full Text] [Related]
2. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
4. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
5. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective.
McAdam-Marx C; McGarry LJ; Hane CA; Biskupiak J; Deniz B; Brixner DI
J Manag Care Pharm; 2011 Sep; 17(7):531-46. PubMed ID: 21870894
[TBL] [Abstract][Full Text] [Related]
6. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
7. The Economic Burden of Comorbid Obstructive Sleep Apnea Among Patients with Chronic Obstructive Pulmonary Disease.
Hong YD; Onukwugha E; Slejko JF
J Manag Care Spec Pharm; 2020 Oct; 26(10):1353-1362. PubMed ID: 32996389
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of acute steroid-refractory graft-versus-host disease in commercially insured pediatric patients.
Grabner M; Strati E; Sandman K; Forsythe A
J Manag Care Spec Pharm; 2021 May; 27(5):607-614. PubMed ID: 33908282
[No Abstract] [Full Text] [Related]
9. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis.
Almony A; Keyloun KR; Shah-Manek B; Multani JK; McGuiness CB; Chen CC; Campbell JH
J Manag Care Spec Pharm; 2021 Sep; 27(9):1260-1272. PubMed ID: 34464210
[No Abstract] [Full Text] [Related]
12. Health Care Utilization and Economic Burden in Patients with Central Precocious Puberty: An Assessment of the Commercially Insured and Medicaid Populations.
Klein K; Soliman AM; Bonafede M; Nelson JK; Grubb E
J Manag Care Spec Pharm; 2019 Jul; 25(7):836-846. PubMed ID: 31232203
[TBL] [Abstract][Full Text] [Related]
13. All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.
Lefebvre P; Laliberté F; Nutescu EA; Duh MS; LaMori J; Bookhart BK; Olson WH; Dea K; Schein J; Kaatz S
J Manag Care Pharm; 2012 Jun; 18(5):363-74. PubMed ID: 22663169
[TBL] [Abstract][Full Text] [Related]
14. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States.
Lu M; Oladapo A; Wu Y; Farahbakhshian S; Ewenstein B
J Manag Care Spec Pharm; 2021 Feb; 27(2):175-185. PubMed ID: 33307935
[No Abstract] [Full Text] [Related]
17. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
18. The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States.
Ogbomo A; Tsang Y; Mallampati R; Panjabi S
J Manag Care Spec Pharm; 2022 Jun; 28(6):608-616. PubMed ID: 35621726
[No Abstract] [Full Text] [Related]
19. Direct Costs Incurred Among Women Undergoing Surgical Procedures to Treat Uterine Fibroids.
Harrington A; Bonine NG; Banks E; Shih V; Stafkey-Mailey D; Fuldeore RM; Yue B; Ye JM; Ta JT; Gillard P
J Manag Care Spec Pharm; 2020 Jan; 26(1-a Suppl):S2-S10. PubMed ID: 31958025
[TBL] [Abstract][Full Text] [Related]
20. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
